Zobrazeno 1 - 10
of 76
pro vyhledávání: ''
Autor:
Heidi S. Donovan, Susan M. Sereika, Lari B. Wenzel, Robert P. Edwards, Judith E. Knapp, Susan H. Hughes, Mary C. Roberge, Teresa H. Thomas, Sara Jo Klein, Michael B. Spring, Susan Nolte, Lisa M. Landrum, A. Catherine Casey, David G. Mutch, Robert L. DeBernardo, Carolyn Y. Muller, Stephanie A. Sullivan, Sandra E. Ward
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 40, iss 13
J Clin Oncol
J Clin Oncol
PURPOSE GOG-259 was a 3-arm randomized controlled trial of two web-based symptom management interventions for patients with recurrent ovarian cancer. Primary aims were to compare the efficacy of the nurse-guided (Nurse-WRITE) and self-directed (SD-WR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa37c17b850fe4cd6e7cbf0d6d5a406c
https://escholarship.org/uc/item/5s0946nm
https://escholarship.org/uc/item/5s0946nm
Autor:
Elliot Naidus, Lawrence Fong, David Y. Oh, Nathan Standifer, Jerome Bouquet, Timothy Looney, Li Zhang, Hai Yang
Publikováno v:
Cancer immunology, immunotherapy : CII, vol 70, iss 7
Cancer Immunology, Immunotherapy
Cancer Immunology, Immunotherapy
Immune checkpoint inhibitors (ICI) are designed to activate exhausted tumor-reactive T cells thereby leading to tumor regression. Durvalumab, an ICI that binds to the programmed death ligand-1 (PD-L1) molecule, is approved as a consolidation therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81755443fe7b823829672ac3b3048c5d
https://escholarship.org/uc/item/53t0g7b0
https://escholarship.org/uc/item/53t0g7b0
Autor:
Ding Wang, Bryan A. Faller, Lauren Averett Byers, Ronald H. Yanagihara, Roy H. Decker, Allen M. Chen, Scott N. Gettinger, Mihaela C. Cristea, Karen Kelly, Mary W. Redman, Linda L. Garland, Kathy S. Albain, Megan E. Daly, David R. Gandara, Jacob Sands, Marianna Koczywas, Athanassios Argiris, Jieling Miao
Publikováno v:
Clinical lung cancer, vol 22, iss 4
Clin Lung Cancer
Clin Lung Cancer
BackgroundWe conducted a2-part study to evaluate the incorporation of veliparib, a PARP inhibitor, into chemoradiotherapy (CRT) for stage III non-small-cell lung cancer.Patients and methodsIn the phase I part, patients were treated successivelyat3dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::393a26ccbd48bf1e54aabad205028d60
https://escholarship.org/uc/item/8xv6h4ff
https://escholarship.org/uc/item/8xv6h4ff
Autor:
Carmen García-Ruiz, Susana Nuñez, Carmen G. Vallejo, Maria J. Monte, Juan Carlos García-Valdecasas, Josep Fuster, Vicent Ribas, Joana Ferrer, Anna Baulies, Michael Karin, Fernando Civeira, Lucía Baila-Rueda, Jose J.G. Marin, Laura Conde de la Rosa, Ana Cenarro, José C. Fernández-Checa
Publikováno v:
Journal of hepatology, vol 74, iss 6
Digital.CSIC. Repositorio Institucional del CSIC
instname
Hepatobiliary Surg Nutr
Digital.CSIC. Repositorio Institucional del CSIC
instname
Hepatobiliary Surg Nutr
Background & Aims Besides their physiological role in bile formation and fat digestion, bile acids (BAs) synthesised from cholesterol in hepatocytes act as signalling molecules that modulate hepatocellular carcinoma (HCC). Trafficking of cholesterol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2f31bf7f148b908fb92597233bae932
https://escholarship.org/uc/item/15v896ht
https://escholarship.org/uc/item/15v896ht
Autor:
Karen Kelly, Suresh S. Ramalingam, David R. Gandara, Jeffrey D. Bradley, Lawrence H. Schwartz, Natasha B. Leighl, Philip C. Mack, Katherine Minichiello, Saloni H. Tanna, Thomas E. Stinchcombe, Vassiliki A. Papadimitrakopoulou, Roy S. Herbst, Susanne M. Arnold, Saiama N. Waqar, Fred R. Hirsch, Mary W. Redman, Ryan S. Raddin
Publikováno v:
Clinical lung cancer, vol 22, iss 3
Clin Lung Cancer
Clin Lung Cancer
Introduction Lung-MAP S1400K was designed to evaluate the response to telisotuzumab vedotin, an antibody-drug conjugate targeting c-MET, in patients with c-MET–positive squamous cell carcinoma (SCC). Patients and Methods Patients with previously tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74b41b15434c2a87c39e5d7cb2f1fe4c
https://escholarship.org/uc/item/1w44k2fs
https://escholarship.org/uc/item/1w44k2fs
Autor:
Ann Cleverly, Amin Yaqubie, Michael Lahn, Karim A. Benhadji, Yumin Zhao, Ivelina Gueorguieva, Ghassan K. Abou-Alfa, James J. Harding, Richard K. G. Do, Robin Kate Kelley
Publikováno v:
Cancer medicine, vol 10, iss 9
Cancer Medicine, Vol 10, Iss 9, Pp 3059-3067 (2021)
Cancer Medicine
Cancer Medicine, Vol 10, Iss 9, Pp 3059-3067 (2021)
Cancer Medicine
Background Preclinical data suggest that vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)‐β signaling interact to stimulate angiogenesis and suppress antitumor immune responses. Thus, combined inhibition of both pathw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0280d809d5d29dada11713ad6c017827
https://escholarship.org/uc/item/9k64c4jr
https://escholarship.org/uc/item/9k64c4jr
Autor:
Vadim S. Koshkin, Sima P. Porten, Anthony C. Wong, David Y. Oh, Lawrence Fong, Arpita Desai, Ivan de Kouchkovsky, Eric J. Small, Francis Wright, Hansen Ho, Daniel Kwon, Errol J. Philip, Raj S. Pruthi, Divya Natesan, Terence W. Friedlander, Son Ho, Li Zhang, Jonathan Chou, Emily Chan, Franklin W. Huang, Daniel M Kim
Publikováno v:
Journal for immunotherapy of cancer, vol 9, iss 5
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
BackgroundImmune checkpoint inhibitors (ICI) can achieve durable responses in a subset of patients with locally advanced or metastatic urothelial carcinoma (aUC). The use of tumor genomic profiling in clinical practice may help suggest biomarkers to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6155b5d264e08c0cca1f68c52f39ea2d
https://escholarship.org/uc/item/9846n1dp
https://escholarship.org/uc/item/9846n1dp
Autor:
Anup Patel, Jean-Francois Martini, Bernard Escudier, Xun Lin, Robert J. Motzer, Alain Ravaud, Daniel J. George, Allan J. Pantuck, Michael Staehler, Mariajose Lechuga
Publikováno v:
Future oncology (London, England), vol 17, iss 4
Future Oncology
Future Oncology
Aim: To examine the prognostic value of the platelet-to-lymphocyte ratio (PLR) in the adjuvant renal cell carcinoma setting. Materials & methods: Patients received adjuvant sunitinib (50 mg/day; 4 weeks on/2 weeks off) or placebo. The primary end poi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fa719a0144154a8e54bb767da530cdf
https://escholarship.org/uc/item/7tp3w44v
https://escholarship.org/uc/item/7tp3w44v
Autor:
Leora Horn, Mary Ann Melnick, James C. Moon, Megan Baumgart, Rogerio Lilenbaum, Thomas E. Stinchcombe, Sarah B. Goldberg, Katerina Politi, Scott N. Gettinger, Sandeep H. Mashru, Mary W. Redman, David R. Gandara, Jieling Miao, Everett H. Chen, Roy S. Herbst, Karen Kelly
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 34
PURPOSE The irreversible ErbB family tyrosine kinase inhibitor (TKI) afatinib plus the EGFR monoclonal antibody cetuximab was previously shown to overcome resistance to EGFR TKIs. We studied whether the combination of afatinib plus cetuximab compared
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b44f7fce1cb4d66537a60804275fe22
https://escholarship.org/uc/item/3g8545rn
https://escholarship.org/uc/item/3g8545rn
Autor:
Eric A. Collisson, Wilko Weichert, Brian Lu, Sarah E. Umetsu, Katja Steiger, Henry Hongo, Robert J. Torphy, David Horst, Nancy M. Joseph, Honglin Jiang, Edik M. Blais, Michael J. Pishvaian, Kimberly McGregor, Mark Kriegsmann, Zhen J. Wang, Alexa J. Ritchie, Valerie M. Weaver, Keith E. Volmar, Jen Jen Yeh, Michael A. Hollingsworth, Margaret A. Tempero, Mingyu Li, Connor Stashko
Publikováno v:
The Journal of clinical investigation, vol 130, iss 9
J Clin Invest
J Clin Invest
Desmoplasia describes the deposition of extensive extracellular matrix and defines primary pancreatic ductal adenocarcinoma (PDA). The acellular component of this stroma has been implicated in PDA pathogenesis and is being targeted therapeutically in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a32880110704508a8572529144b1cd2a
https://escholarship.org/uc/item/2vb45770
https://escholarship.org/uc/item/2vb45770